@Article{,
AUTHOR = {Jarad Martin, Robert Bristow, Padraig Warde},
TITLE = {Low and intermediate risk prostate cancer – role of hormonal therapy with external beam radiation therapy},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {13},
YEAR = {2006},
NUMBER = {Suppl.2},
PAGES = {63--67},
URL = {http://www.techscience.com/CJU/v13nSuppl.2/63357},
ISSN = {1488-5581},
ABSTRACT = {Risk categorization based on pre-treatment PSA, clinical
stage and Gleason score is now widely used in the
management of patients with localized prostate cancer. In
patients with low-risk disease (cT1-T2a, PSA < 10 ng/ml
and Gleason score ≤ 6) there is no role for the routine use
of adjunctive hormonal therapy. In intermediate-risk
patients (T1-T2, PSA < 20 ng/ml and Gleason ≤ 7) there
is some evidence to suggest improved outcomes with neo-adjuvant hormonal therapy when low-dose external beam
radiation therapy (EBRT) is used. However, with
appropriate modern dose EBRT there is little data to support
the use of routine adjunctive hormonal therapy and this
should be done only in the context of a clinical trial.},
DOI = {}
}